DelMar Pharmaceuticals Inc. (NASDAQ: DMPI) Starts Presentation at 12th Annual LD Micro Main Event
DelMar Pharmaceuticals (NASDAQ: DMPI) is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. The company’s lead product candidate, VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven, Phase 2 clinical trial for the treatment of Unmethylated MGMT recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. The company is also exploring VAL-083 in a Phase 2 trial as a therapy for front-line Unmethylated MGMT GBM and we may study other solid tumors, including ovarian cancer and pediatric CNS tumors. For more information, visit the…







